A Randomized Phase II Study Of Interleukin-2 In Combination With Three Different Doses Of Bryostatin In Patients With Renal Cell Carcinoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bryostatin-1 (Primary) ; Interleukin-2 (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 24 Jan 2013 Biomarkers information updated
- 09 May 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
- 31 Oct 2007 Status change from suspended to in progress.